| Literature DB >> 32343676 |
Susmita G Ramanand1, Yong Chen2,3, Jiapei Yuan1, Kelly Daescu2, Maryou Bk Lambros4, Kathleen E Houlahan5,6,7,8,9,10, Suzanne Carreira4, Wei Yuan4, GuemHee Baek1, Adam Sharp4, Alec Paschalis4, Mohammed Kanchwala11, Yunpeng Gao1, Adam Aslam1, Nida Safdar1, Xiaowei Zhan12, Ganesh V Raj13, Chao Xing8,9,14, Paul C Boutros6,7,8,9,10, Johann de Bono4, Michael Q Zhang2,15, Ram S Mani1,13,16.
Abstract
Transcriptional dysregulation is a hallmark of prostate cancer (PCa). We mapped the RNA polymerase II-associated (RNA Pol II-associated) chromatin interactions in normal prostate cells and PCa cells. We discovered thousands of enhancer-promoter, enhancer-enhancer, as well as promoter-promoter chromatin interactions. These transcriptional hubs operate within the framework set by structural proteins - CTCF and cohesins - and are regulated by the cooperative action of master transcription factors, such as the androgen receptor (AR) and FOXA1. By combining analyses from metastatic castration-resistant PCa (mCRPC) specimens, we show that AR locus amplification contributes to the transcriptional upregulation of the AR gene by increasing the total number of chromatin interaction modules comprising the AR gene and its distal enhancer. We deconvoluted the transcription control modules of several PCa genes, notably the biomarker KLK3, lineage-restricted genes (KRT8, KRT18, HOXB13, FOXA1, ZBTB16), the drug target EZH2, and the oncogene MYC. By integrating clinical PCa data, we defined a germline-somatic interplay between the PCa risk allele rs684232 and the somatically acquired TMPRSS2-ERG gene fusion in the transcriptional regulation of multiple target genes - VPS53, FAM57A, and GEMIN4. Our studies implicate changes in genome organization as a critical determinant of aberrant transcriptional regulation in PCa.Entities:
Keywords: Epigenetics; Genetics; Oncology; Prostate cancer; Transcription
Mesh:
Substances:
Year: 2020 PMID: 32343676 PMCID: PMC7410051 DOI: 10.1172/JCI134260
Source DB: PubMed Journal: J Clin Invest ISSN: 0021-9738 Impact factor: 14.808